Találati lista | Tudóstér

001-es BibID:	BIBFORM073014
Első szerző:	Berta Eszter (belgyógyász)
Cím:	Early stage Graves' disease is uniformly accompanied by orbital immune activity even in patients who fail to develop orbithopathy during follow-up / Eszter Berta, Miklós Bodor, László Galuska, György Paragh, Annamária Erdei, Annamária Gazdag, Bernadett Ujhelyi, Ervin Berényi, Mónika Katkó, Andrea Gazsó, Endre V. Nagy
Dátum:	2018
ISSN:	0947-7349
Megjegyzések:	Purpose. Graves' orbitopathy (GO) is a complication of Graves' disease (GD), the development of which cannot be predicted at the time of diagnosis of GD. Our aims were (i) to test if orbital 99mTc-labelled diethylenetriamine pentaacetic acid single-photon emission computer tomography (DTPA SPECT) can predict development of GO later during the course of the disease and (ii) to study whether orbital immune activity can be detected in GD patients who do not develop GO during follow-up.Methods. Fifty-four orbits of 27 patients with newly diagnosed GD were entered into the case-control study. Individuals showing signs of GO at enrolment were excluded. During the two-year follow up, eye signs were recorded every 3 months. Orbital DTPA uptakes on SPECT images were measured when entering the study and at the end of the follow-up period, or when clinical signs of GO developed, whichever occurred first.Results. During thefollow up, 6 patients (22%) were diagnosed with GO. There was no significant difference between the initial DTPA uptakes of the patients with or without later developing GO (10.45?1.72 MBq/cm vs. 9.18?1.18 MBq/cm3 respectively). However, the DTPA uptakes of both GD groups (ie. with and without GO) were higher than that of the control group (7.45?1.36 MBq/cm3, p<0.05).Conclusions. We have shown that GD is accompanied by moderate orbital immune activity in GD patients without GO, irrespective of later development of GO. Why this orbital autoimmunity remains subclinical in the majority of the cases, and progresses into clinically detectable GO in others, remains unclear.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban pajzsmirigy endokrin orbitopathia
Megjelenés:	Experimental And Clinical Endocrinology & Diabetes. - 126 : 10 (2018), p. 628-631. -
További szerzők:	Bodor Miklós (1969-) (belgyógyász, endokrinológus) Galuska László (1946-) (belgyógyász, izotópdiagnoszta) Paragh György (1953-) (belgyógyász) Erdei Annamária (1976-) (belgyógyász) Gazdag Annamária (1979-) (belgyógyász) Ujhelyi Bernadett (1981-) (szemész) Berényi Ervin (1964-) (radiológus) Katkó Mónika (1980-) (biológus) Gazsó Andrea Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM050268
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects / Hajnalka Lőrincz, Mónika Katkó, Mariann Harangi, Sándor Somodi, Krisztina Gaál, Péter Fülöp, György Paragh, Ildikó Seres
Dátum:	2014
ISSN:	0300-0664
Megjegyzések:	OBJECTIVE: Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. PATIENTS AND METHODS: Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). RESULTS: We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P < 0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. CONCLUSION: Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban nondiabetic obese Low-density lipoprotein LDL cholesterol
Megjelenés:	Clinical Endocrinology. - 81 : 3 (2014), p. 370-377. -
További szerzők:	Katkó Mónika (1980-) (biológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász) Gaál Krisztina (1976-) (belgyógyász szakorvos) Fülöp Péter (1974-) (belgyógyász, endokrinológus, lipidológus) Paragh György (1953-) (belgyógyász) Seres Ildikó (1954-) (biokémikus)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0031 TÁMOP 84196 OTKA
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: